Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Ionis Pharmaceuticals Inc. Revenue & Financial Statements
Ionis Pharmaceuticals Inc. reported revenue of $705.1M for the fiscal year ended December 31, 2024, down 10.5% year over year, with net income of $(453.9M) and diluted EPS of $-3.04.
- Company
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2024
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | 729.3M | 810.5M | 587.4M | 787.6M | 705.1M |
| Cost of revenue | 11.9M | 10.8M | 14.1M | 9.1M | 11.2M |
| Gross profit | 717.3M | 799.6M | 573.3M | 778.5M | 693.9M |
| Operating income | (172.1M) | (30.2M) | (410.2M) | (353.7M) | (475.1M) |
| Pretax income | (172.7M) | (30.0M) | (258.5M) | (334.7M) | (460.7M) |
| Net income | (451.5M) | 224.6M | (269.7M) | (366.3M) | (453.9M) |
| Diluted EPS | -3.23 | -0.20 | -1.90 | -2.56 | -3.04 |
| EBITDA | (158.7M) | (14.7M) | (395.9M) | (343.4M) | (465.5M) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q2 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 119.5M | 225.2M | 133.8M | 226.6M | 131.6M | 452.0M | 156.7M | — |
| Cost of revenue | 2.2M | 4.2M | 1.1M | 3.8M | 1.5M | 4.2M | 2.3M | — |
| Gross profit | 117.3M | 221.1M | 132.7M | 222.7M | 130.1M | 447.9M | 154.4M | — |
| Operating income | (149.5M) | (66.1M) | (148.7M) | (110.8M) | (146.9M) | 139.8M | (160.2M) | — |
| Pretax income | (142.7M) | (66.2M) | (144.1M) | (107.0M) | (146.8M) | 123.5M | (128.4M) | — |
| Net income | (142.8M) | (66.3M) | (140.5M) | (104.3M) | (146.9M) | 123.6M | (128.6M) | — |
| Diluted EPS | -0.98 | -0.45 | -0.95 | -0.66 | -0.93 | 0.70 | -0.80 | — |
| EBITDA | (147.0M) | — | (146.3M) | (108.6M) | (144.6M) | — | (157.9M) | — |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 2.6B | 2.5B | 3.0B | 3.0B | 3.5B |
| Current assets | 2.3B | 2.2B | 2.6B | 2.6B | 3.0B |
| Cash & equivalents | 869.2M | 276.5M | 399.3M | 242.1M | 372.3M |
| Total liabilities | 1.8B | 2.0B | 2.6B | 2.4B | 3.0B |
| Current liabilities | 240.6M | 311.6M | 448.1M | 309.3M | 781.6M |
| Long-term debt | — | 1.2B | 1.2B | 1.2B | 1.3B |
| Total debt | — | 1.2B | 1.2B | 1.2B | 1.8B |
| Stockholders’ equity | 771.7M | 572.9M | 386.7M | 588.4M | 489.1M |
| Net debt | — | 899.4M | 841.9M | 960.5M | 1.4B |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 30.8M | (274.4M) | (307.5M) | (500.9M) | (268.6M) |
| Investing cash flow | 194.9M | (262.6M) | (214.1M) | (134.0M) | (277.8M) |
| Financing cash flow | 245.9M | (55.3M) | 644.1M | 478.1M | 675.8M |
| Capital expenditure | 12.0M | 15.7M | 23.8M | 45.3M | 51.4M |
| Free cash flow | 18.8M | (290.1M) | (331.3M) | (546.2M) | (320.0M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 120.7M | 100.3M | 105.8M | 130.2M | 133.9M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every IONS filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.